Pharvaris Advances HAE Pipeline with Key Trials, NDA Submission on Track
Event summary
- Completed enrollment in CHAPTER-3 pivotal study for deucrictibant XR, with topline data expected in 3Q2026.
- On track to submit NDA for deucrictibant IR in 1H2026 for on-demand HAE treatment.
- CREAATE Phase 3 study for AAE-C1INH ongoing with enrollment progressing as planned.
- Cash position at €292 million as of December 31, 2025.
The big picture
Pharvaris is advancing its pipeline for bradykinin-mediated diseases, with key milestones in 2026 that could position deucrictibant as a differentiated oral treatment for HAE and AAE-C1INH. The company's strategic focus on both prophylactic and on-demand treatments aims to address significant unmet needs in angioedema management. With a strong cash position, Pharvaris is well-funded to navigate these critical inflection points, though execution risks and regulatory timelines remain key variables.
What we're watching
- Regulatory Timing
- Whether the NDA submission for deucrictibant IR will meet the 1H2026 target and the potential impact of regulatory reviews on approval timelines.
- Clinical Data Impact
- How the topline data from the CHAPTER-3 study in 3Q2026 will influence the market perception of deucrictibant XR's efficacy and safety profile.
- Financial Discipline
- The pace at which Pharvaris can maintain financial discipline while advancing multiple clinical programs and preparing for potential commercialization.
Related topics